Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Rua Life Sciences Plc LSE:RUA London Ordinary Share GB0033360586 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 37.25 35.50 39.00 37.25 37.25 37.25 9,900 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 1.5 -1.6 -8.2 - 8

RUA Life Sciences PLC Buy Back and Cancellation of Deferred Shares

24/06/2021 1:01pm

UK Regulatory (RNS & others)


Rua Life Sciences (LSE:RUA)
Historical Stock Chart


From Jun 2020 to Jun 2022

Click Here for more Rua Life Sciences Charts.

TIDMRUA

RNS Number : 0383D

RUA Life Sciences PLC

24 June 2021

24 June 2021

RUA Life Sciences plc

("RUA" or the "Company")

Buy Back and Cancellation of Deferred Shares

Further to its announcement released on 23 June 2021, RUA Life Sciences plc (AIM: RUA), the holding company of a group of medical device businesses focused on the exploitation of Elast-Eon(TM) , a long-term implantable biostable polymer, is pleased to announce that the Company has completed the Buy Back of all of its Deferred Shares, details of which were set out in the Circular sent to Shareholders dated 4 June 2021. All of the Deferred Shares acquired have been cancelled. Following the repurchase and cancellation of the Deferred Shares, there are no Deferred Shares in issue and the New Articles have been adopted.

The Company's issued share capital following completion of the Buy Back of all of its Deferred Shares comprises 22,184,798 Ordinary Shares of which none are held in treasury. The above figure of 22,184,798 may be used by Shareholders as the denomination for the calculations by which they will determine if they are required to notify their interest or a change in their interest in the voting rights in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the Circular sent to Shareholders dated 4 June 2021.

For more information please contact:

RUA Life Sciences plc

   Bill Brown, Chairman                                         Tel: +44 (0) 77 3071 8296 
   David Richmond, CEO                                      Tel: +44 (0) 78 9999 6400 

Shore Capital (Nomad and Joint Broker)

   Tom Griffiths/David Coaten                               Tel: +44 (0) 20 7408 4080 
   Cenkos Securities plc (Joint Broker)                 Tel: +44 (0) 20 7397 8900 

Russell Cook/Max Gould (Corporate Finance)

Michael Johnson (Sales)

About RUA Life Sciences

The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.

Our vision is to improve the lives of millions of patients by improving and enabling medical devices with Elast-Eon(TM), a long-term implantable polyurethane.

Whether it is licensing Elast-Eon(TM), manufacturing a device or component or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.

Elast-Eon(TM)'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 7 million implants and over 14 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.

The Group's four business units are:

 
 RUA Medical :       End-to-end contract designer and manufacturer 
                      of medical devices and implantable fabric specialist. 
 RUA Biomaterials:   Licensor of Elast-Eon(TM) polymers to the medical 
                      device industry. 
 RUA Vascular:       Commercialisation of large bore polymer sealed 
                      grafts and soft tissue patches. 
 RUA Structural      Development of polymeric leaflet systems for 
  Heart:              heart valves. 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

POSUSVARAKUNUAR

(END) Dow Jones Newswires

June 24, 2021 08:01 ET (12:01 GMT)

1 Year Rua Life Sciences Chart

1 Year Rua Life Sciences Chart

1 Month Rua Life Sciences Chart

1 Month Rua Life Sciences Chart
ADVFN Advertorial
Your Recent History
LSE
RUA
Rua Life S..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220625 17:14:10